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Abstract
 
We explored the role of Gi protein signaling in the regulation of interleukin (IL)-12 produc-
tion and T helper cell type 1 (Th1) T cell differentiation. In initial studies, we showed that
treatment of normal mice with pertussis toxin (PT), which inhibits Gi protein signaling, en-
hanced the capacity of splenocytes to produce IL-12 in response to both microbial and nonmi-
crobial stimuli. In addition, PT treatment increased the production of tumor necrosis factor
(TNF)-
 
a
 
 and IL-10 by stimulated cells. These findings were corroborated by the fact that un-
treated Gi2
 
a
 
2
 
/
 
2
 
 mice exhibited enhanced production of IL-12 and TNF-
 
a
 
 by splenocytes,
and of IL-12 p40 by purified spleen CD8
 
a
 
1
 
 lymphoid dendritic cells. Finally, we showed that
while normal BALB/c mice infected with 
 
Leishmania major
 
 exhibited a nonhealing phenotype,
those treated with PT when infection was initiated exhibited a healing phenotype along with
an enhancement of leishmania-specific Th1 responses in draining lymph nodes. Further, heal-
ing was prevented by coadministration of anti–IL-12 and PT. These data demonstrate that en-
dogenous Gi protein signaling has a primary role in the regulation of IL-12 production and the
induction of Th1 responses in vivo.
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Introduction
 
Prior studies from this and other laboratories have demon-
strated that signaling via Gi protein–coupled seven trans-
membrane domain receptors (7TDR) can inhibit the pro-
duction of IL-12 by APCs and the subsequent induction of
Th1 responses (1–5). Thus, it has been shown that the CC
chemokine macrophage chemoattractant protein (MCP)-
1–4, and the natural chemoattractant C5a, when added ex-
ogenously, can suppress IL-12 production from APCs in
vitro (1, 2). In addition, treatment of mice with MCP-1
has been shown to inhibit the induction of septic shock af-
ter exposure to LPS, and to enhance the induction of oral
tolerance (3, 5). These effects of MCP-1 are consistent
with its ability to inhibit IL-12 production, as IL-12 has
been proposed to have enhancing and inhibitory roles, re-
spectively, in these processes. Finally, tetrahydrocannabinol
and morphine, which act via Gi protein–coupled cannab-
inoid, and opioid receptors have been shown to inhibit the
induction of Th1 responses in vivo (6, 7).
Although these studies demonstrated that exogenous ap-
plication of 7TDR ligands can result in the suppression of
IL-12 production and Th1 responses, they did not address
the role of endogenously produced 7TDR ligands in the
regulation of normally occurring immune responses in
vivo. In this report, we first show that treatment of normal
mice with pertussis toxin (PT), which acts to inhibit Gi
protein signaling in leukocytes (8, 9), results in an en-
hanced capacity of splenocytes to produce IL-12 in re-
sponse to both microbial and nonmicrobial stimuli. To rule
out the possibility that PT acts via a non–Gi-dependent
pathway (10), we show that splenocytes and dendritic cells
(DCs) from mice deficient in Gi2
 
a
 
, a member of the Gi
protein family, exhibit enhanced production of IL-12 simi-
lar to that seen with cells from PT-treated wild-type (WT)
mice. Finally, we show that PT treatment of BALB/c mice
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infected with 
 
Leishmania major 
 
results in a healing pheno-
type and the enhancement of leishmania-specific Th1
responses in draining LNs. Taken together, these data
strongly support the view that Gi protein signaling plays a
central role in the regulation of IL-12 production and the
induction of Th1 responses in vivo.
 
Materials and Methods
 
Mice.
 
Gi2
 
a
 
-deficient (Gi2
 
a
 
2
 
/
 
2
 
) mice on the C57BL/6 back-
ground were bred from homozygous breeding pairs (11) origi-
nally provided by Baylor College of Medicine (Houston, TX).
Age- and sex-matched WT C57BL/6 control mice as well as fe-
male BALB/c mice were obtained from the National Cancer In-
stitute, National Institutes of Health. All mice used were between
8 and 13 wk of age and conventionally housed.
 
Reagents.
 
PT was purchased from List Biological Laborato-
ries. Soluble leishmania antigen (SLA) was prepared as described
previously (12).
 
 
 
Staphylococcus aureus
 
, Cowan’s strain I (SAC; Pan-
sorbin
 
®
 
), was supplied by Calbiochem. Recombinant murine
IFN-
 
g
 
 was purchased from BD PharMingen. LPS (from 
 
Esche-
richia coli
 
, serotype 0127:B8) was purchased from Sigma-Aldrich.
Immunostimulatory CpG-containing oligodeoxynucleotide 1826
(TCCATGACGTTCCTGACGTT; ODN) (13) was synthesized
with a nuclease-resistant phosphorothioate backbone by Operon
Technologies. Recombinant trimerized murine CD40 ligand
(CD40L) was provided by Immunex.
 
Treatment of Animals and Parasite Challenge.
 
8–12-wk-old fe-
male BALB/c mice were treated with 400 ng of PT in 100 
 
m
 
l of
PBS intravenously on days 0 and 2. For antibody treatment, mice
were given 2 mg of anti–murine IL-12 (clone C17.8) or control
antibody on days 0, 2, 4, and 8. The initial treatment with PT
and/or anti–IL-12 was followed by inoculation of 10
 
5
 
 
 
L. major
 
(WHOM/IR/
 
2
 
/173) metacyclic promastigotes into the right
hind footpad (14). Footpad swelling was measured weekly using a
metric caliper. 6–7 wk after infection, mice were killed and
draining LNs were removed for analysis of antigen-specific cy-
tokine responses (see below). In addition, feet from representative
animals were removed and fixed in 10% buffered formalin. Paraf-
fin sections were made and stained with Giemsa stain according
to established procedures.
 
Cell Culture Conditions and Measurement of Cytokine Production.
 
Splenocytes were obtained from Gi2
 
a
 
2
 
/
 
2
 
 mice and WT control
mice and cultured at 2 
 
3
 
 10
 
6
 
 cells/ml in RPMI 1640 (Biosource
International) supplemented with 10% fetal bovine serum (Bio-
source International), 100 
 
m
 
g/ml penicillin, 10 
 
m
 
g/ml strepto-
mycin, 50 
 
m
 
g/ml gentamicin (Life Technologies), 5% Medium
NCTC-109 (Life Technologies), 15 mM Hepes buffer, 0.005
mM 2-ME, and 2 mM 
 
l
 
-glutamine (cRPMI) at 37
 
8
 
C and 6%
CO
 
2
 
. Cells were cultured with the indicated stimuli for 24 h, at
which time supernatants were removed and frozen at 
 
2
 
20
 
8
 
C
until measurement of cytokines. Transiently adherent DCs were
isolated by plating splenocytes on tissue culture dishes and incu-
bating for 1 h at 37
 
8
 
C and 6% CO
 
2
 
. The plates were then washed
with warmed PBS. Transiently adherent DC-enriched cells were
then harvested after an additional 24 h of incubation at 37
 
8
 
C in
cRPMI and stimulated at 6 
 
3
 
 10
 
5
 
 cells/ml. Highly purified lym-
phoid DCs were prepared as described previously (15). In brief,
spleens were digested with collagenase D (400 U/ml; Roche
Molecular Biochemicals) and DNase I (15 
 
m
 
g/ml; Roche Molec-
ular Biochemicals), treated with EDTA (5 mM), and CD11c
 
1
 
cells were positively selected with anti–mouse CD11c-coated
magnetic beads (Miltenyi Biotec). Selected cells were then stained
with PE-labeled anti-CD8
 
a
 
 and FITC-conjugated anti-B220 an-
tibodies, and B220
 
2
 
CD8
 
a
 
1
 
 cells were isolated by flow cytomet-
ric sorting (FACStar™; Becton Dickinson). Sorted DCs (98% for
CD11c
 
1
 
 and CD8
 
a
 
1
 
) were plated at 10
 
5 
 
cells/200 
 
m
 
l and stimu-
lated as indicated. For measurement of leishmania-specific cyto-
kine responses, single cell preparations from draining popliteal LNs
taken from mice 6 wk after parasite infection were plated in trip-
licate in a 96-well microtiter plate at 3 
 
3
 
 10
 
5
 
 cells/200 
 
m
 
l. SLA
was added to cultures at 2.5 
 
m
 
g/ml, and culture supernatants were
analyzed for the presence of cytokines (14). IFN-
 
g
 
 was assessed
by ELISA using antibody pairs from BD PharMingen. The lower
limit of detection was 50 pg/ml for IFN-
 
g
 
. All other cytokines
were assayed by ELISA using the OptEIA™ set reagents (BD
PharMingen) according to the manufacturer’s instructions. The
lower limit of sensitivity for the IL-12p70, IL-12p40, and TNF-
 
a
 
ELISAs was 30 pg/ml, for the IL-10 ELISA was 10 pg/ml, and
for the IL-4 ELISA was 5 pg/ml.
 
Statistical Analysis.
 
Results represent the mean 
 
6 
 
SD where
applicable. Statistical significance of differences was determined
by the Student’s 
 
t
 
 test.
 
Results and Discussion
 
PT is an exotoxin produced by 
 
Bordetella pertussis 
 
with a
hexameric structure similar to cholera toxin and 
 
E. coli
 
heat-labile toxin (8). The pentameric B subunit mediates
binding of the toxin to glycoprotein receptors on many eu-
karyotic cells. After binding, the A subunit of PT enters the
cell and mediates ADP-ribosylation of the 
 
a
 
 subunits of Gi
proteins. ADP-ribosylation results in inactivation of signal-
ing. Thus, in initial studies to address our hypothesis that
Gi protein signaling by endogenously produced 7TDR
ligands will inhibit IL-12 production and Th1 differentia-
tion in vivo, we treated mice with PT and assessed the abil-
ity of splenocytes from treated mice to produce IL-12 upon
stimulation in vitro.
As shown in Fig. 1, we found that splenocytes from
BALB/c mice pretreated with PT produced significantly
higher amounts of IL-12 p40 and IL-12 p70 after exposure
in vitro to the well-established IL-12 inducer SAC and
IFN-
 
g 
 
(for a review, see reference 16) compared with sple-
nocytes from non–PT-treated mice. This was also shown
using unmethylated bacterial DNA sequences containing
CpG motifs (ODNs), which are capable of stimulating IL-12
production in the absence of IFN-
 
g
 
 (17). Interestingly,
both TNF-
 
a
 
 and IL-10 production were also increased by
PT treatment. Because IL-10 has been shown to be capable
of suppressing IL-12 production (18), the fact that IL-10
levels were increased along with IL-12 suggested that the
inhibitory effect of Gi protein signaling on IL-12 produc-
tion is not due to stimulation of IL-10. In the absence of
stimulation in vitro, isolated splenocytes cultured with PT
alone did not produce any of the measured cytokines, sug-
gesting that PT itself does not directly induce the cells to
produce cytokines. Several prior reports are consistent with
the ability of PT to enhance IL-12 production in vivo.
Thus, it has been shown that natural infection by 
 
B. pertus-
sis
 
, as well as vaccination with a whole cell vaccine contain- 
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ing PT, induces a Th1-predominant T cell response (19,
20). In addition, PT can enhance delayed-type hypersensi-
tivity reactions (21) and has been shown to increase the se-
verity of disease in animal models of Th1-mediated autoim-
munity, such as experimental autoimmune encephalomyelitis
(22) and experimental autoimmune uveitis (16).
To demonstrate that the effect of PT on enhancing cy-
tokine production from splenocytes was due to the ability
of PT to ADP-ribosylate and inactivate Gi proteins, and not
to cellular activation by the pentameric B subunit (10) or to
non-Gi protein–mediated signaling, we next examined cy-
tokine production from cells from untreated Gi2
 
a
 
2
 
/
 
2
 
 mice,
i.e., mice with defective Gi2 protein signaling due to tar-
geted disruption of the Gi2
 
a
 
 gene. A role for Gi2 in regu-
lating immune responses was suggested by studies demon-
strating that conventionally housed Gi2
 
a
 
2
 
/
 
2
 
 mice on
certain genetic backgrounds spontaneously develop a Th1-
mediated inflammatory colitis, with high local levels of IL-
12 (11, 23). As shown in Fig. 2 A, we found that whole
splenocytes from Gi2
 
a
 
2
 
/
 
2
 
 mice produced significantly
higher levels of IL-12 p40, IL-12 p70, and TNF-
 
a
 
, and
similar levels of IL-10 after stimulation with SAC and IFN-
 
g
 
or with ODNs, compared with splenocytes from age- and
sex-matched control mice. Interestingly, the degree of in-
crease in levels of IL-12p40, IL-12p70, and TNF-
 
a
 
 was
virtually identical to that seen for the PT-treated WT mice.
Splenocytes from Gi2
 
a
 
2
 
/
 
2
 
 mice were not enriched for cells
capable of producing IL-12, i.e., monocyte/macrophages,
DCs, or B cells, as determined by flow cytometry, com-
pared with WT mice (data not shown). In addition, cell vi-
ability both before and after in vitro stimulation was identi-
cal for cells from both WT and Gi2
 
a
 
2
 
/
 
2
 
 mice (data not
shown), so neither differences in starting cell populations
nor differences in viability were factors influencing the level
of cytokines produced by the Gi2
 
a
 
2
 
/
 
2
 
 cells.
Since it is now clear that DCs are an important source of
IL-12 and are potent inducers of primary T cell responses
(24), we also tested the ability of DCs from Gi2
 
a
 
2
 
/
 
2
 
 mice
to produce IL-12, as well as other cytokines in response to
bacterial and T cell stimuli. As shown in Fig. 2 B, stimula-
tion of transiently adherent DC-enriched (40–60%) spleen
cells with SAC, LPS, or a trimerized form of recombinant
CD40L (to stimulate DCs via surface-expressed CD40) and
IFN-
 
g
 
 or ODNs alone resulted in levels of IL-12 p70 and
Figure 1. Treatment of mice with PT enhances IL-12 and TNF-a
production by cultured splenocytes. This enhancement is seen with T
cell–dependent and –independent stimuli and is not due to the suppres-
sion of IL-10 production. BALB/c mice were given 400 ng PT in 100 ml
PBS. Controls were sex- and age-matched untreated BALB/c mice. Sple-
nocytes from individual mice (n 5 5) were prepared 20 h after PT treat-
ment and stimulated with SAC (0.02%) and IFN-g (10 ng/ml), or with
ODNs (5 mg/ml). (A) IL-12 p70 production. (B) IL-12 p40 production.
(C) TNF-a production. (D) IL-10 production. Data are presented as
mean value 6 SD and are representative of three separate experiments
producing similar results. *P , 0.008.
Figure 2. Increased IL-12 and TNF-a production by whole spleno-
cytes and transiently adherent DC-enriched spleen cells from Gi2a2/2
mice. Splenocytes and DC-enriched spleen cells from individual Gi2a2/2
(n 5 3) and WT (n 5 3) mice were prepared and stimulated with SAC
(0.02%), LPS (1 mg/ml), or CD40LT (4 mg/ml), together with IFN-g
(10 ng/ml), or with ODNs (5 mg/ml) alone. (A) Cytokine levels from
whole splenocytes. (B) Cytokine levels from DC-enriched spleen cells.
Data are presented as mean value 6 SD and are representative of four sep-
arate experiments producing similar results. *P , 0.005; **P . 0.5.1608 Gi Protein Signaling and Th1 Differentiation
IL-12 p40 that were two- to fivefold higher than from
control cells. In addition, DC-enriched cells from Gi2a2/2
mice produced higher levels of TNF-a and similar
amounts of IL-10 compared with cells from control mice.
It has recently been shown that the subpopulation of
murine spleen DCs that expresses CD8a, and is thought to
be derived from a lymphoid precursor, has an enhanced ca-
pacity to produce IL-12 and to induce the differentiation of
Th1 cells compared with CD8a2CD11b1 myeloid-derived
spleen DCs (25, 26). Therefore, another possible explana-
tion for why whole spleen DC populations from Gi2a2/2
mice produce more IL-12 is that DC populations in such mice
are skewed to a lymphoid phenotype. To test this possibil-
ity, we analyzed freshly isolated CD11c1 spleen DCs from
Gi2a2/2 and control mice for the expression of CD8a.
We found no difference in the proportions of CD8a1 and
CD8a2 CD11c1 DCs in the spleens of Gi2a2/2 and WT
mice (data not shown).
Next, we isolated highly purified CD8a1 DCs from
spleens of Gi2a2/2 and normal mice, and tested their abil-
ity to produce IL-12. As shown in Table I, consistent with
the other findings from this study, the CD8a1 DCs from
Table I. In Vitro Production of IL-12 p40 by Highly Purified 
CD8a1 DCs from Gi2a2/2 and WT Mice
IL-12 p40
CD8a1 DCs WT Gi2a2/2
pg/ml
Unstimulated ,30 208.24 (6 59.71)*
SAC/IFN-g 1,130.93 (6 119.42) 6,669.02 (6 345.70)*
*P , 0.005.
Figure 3. In vivo treatment with PT protects BALB/c mice
from L. major infection. BALB/c mice were given 400 ng PT in-
travenously on days 0 and 2, and 2 mg anti–IL-12 or control anti-
body (controlAb) intraperitoneally on days 0, 2, 4, and 8. Mice
were challenged in the hind footpad with 105 live L. major meta-
cyclic promastigotes 2 h after the first dose of PT. (A) Footpad
thickness was measured weekly. Data are presented as mean value
6 SD for five individual mice, and are representative of two ex-
periments producing similar results. (B) Giemsa-stained paraffin
sections of footpads from representative control or PT-treated
mice. An arrow indicates an amastigote inside a macrophage (orig-
inal magnification: 3100).1609 He et al. Brief Definitive Report
Gi2a2/2 mice produced significantly higher levels of IL-12
p40 than CD8a1 DCs from WT mice. These data support
the hypothesis that PT, when given to WT mice, acts pri-
marily by its ability to inhibit Gi protein signaling. In addi-
tion, they support a primary role for the specific Gi protein,
Gi2, in immune regulation.
In a final series of studies, we determined the biological
significance of Gi signaling pathways on the development
of Th1 responses in vivo by assessing the effect of PT on the
immune response to L. major, a well-studied infectious dis-
ease model whose resolution depends on an adequate Th1
response (27, 28). In using this model, we took advantage
of the fact that L. major infection of BALB/c mice results in
progressive disease that correlates with the lack of a signifi-
cant IFN-g response to leishmanial antigens in draining
LNs. This in turn has been shown to be due to an early Th2
(IL-4) response that can be negated by the administration of
IL-12 and redirection of the response down the Th1 path-
way (29). Thus, if PT induces Th1 responses, as suggested
by the data presented above, it should have the same effect
on L. major infection as IL-12. To examine this hypothesis,
we treated BALB/c mice with PT at the time of infection
and 48 h later. As shown in Fig. 3 and Fig. 4, such treat-
ment resulted in a healing phenotype, which was accompa-
nied by enhanced IFN-g and TNF-a production by cells
from the draining LNs after stimulation in vitro with L. ma-
jor–specific antigens. In addition, IL-10 production by these
cells was enhanced, again supporting the probability that
PT does not act to increase IL-12 and IFN-g production by
inhibiting IL-10. In contrast, IL-4 production was low and
not significantly different between cells from PT-treated
and untreated mice. The latter finding is consistent with
prior studies demonstrating that the induction of increased
IFN-g–producing T cells, rather than a reduction of IL-4–
producing T cells, correlates with protection in this model
(30). As expected, when anti–IL-12 was coadministered
with PT, the enhanced production of IFN-g, IL-10, and
TNF-a by stimulated LN cells was not seen, and a non-
healing phenotype was again seen, as in the untreated mice.
To confirm the lack of footpad swelling seen in the PT-
treated mice was due to the elimination of parasites and not
simply to a lack of influx of immune or inflammatory cells,
we sectioned the feet of representative mice 6 wk after in-
fection. As shown in Fig. 3 B, feet of control mice were
significantly infected, as shown by the presence of visible
amastigotes throughout the section. In contrast, feet from
PT-treated mice had few, if any, visible amastigotes and had
modest infiltration by lymphocytes.
Taken together, the data presented here demonstrate a
major role for Gi protein signaling in the regulation of
proinflammatory cytokine production from APCs, includ-
ing CD8a1 DCs in mice. They also show that PT can en-
hance the Th1 response to L. major in susceptible BALB/c
mice, resulting in protection against progressive disease.
The fact that reversal of disease susceptibility was prevented
by the coadministration of anti–IL-12 is consistent with the
hypothesis that PT directly enhances the production of IL-
12, which then drives increased Th1 development and pro-
tection in vivo. However, it is also likely that the increased
production of TNF-a after PT treatment contributes to
protection from disease by driving IFN-g production by
NK cells and by enhancing the effects of IFN-g on nitric
oxide–mediated parasite killing by host cells. In contrast,
the effect of PT is unlikely to be due to an inhibitory effect
on immune cell trafficking, since this should result in the
inhibition rather than the enhancement of host resistance.
An implication of these data is that there is a constitutive
suppression of proinflammatory cytokine production in
vivo which is mediated by 7TDR ligands that activate Gi
proteins, particularly Gi2. Among the candidate molecules
that mediate such negative signals are chemokines, since we
have demonstrated that selective chemokines (MCP-1–4,
FMLP, and C5a, but not regulated upon activation, normal
T cell expressed and secreted chemokine [RANTES], mac-
rophage inflammatory protein [MIP]-1a, MIP-1b, or stro-
mal cell–derived factor 1) suppress IL-12 production from
human monocytes in vitro (1). One intriguing possibility in
this regard is that endogenous production of MCP proteins
by monocyte/macrophages upon stimulation with bacterial
products results in an autocrine regulation of proinflamma-
tory cytokine production after binding and signaling via
surface-expressed CC chemokine receptor 2 (CCR2).
Figure 4. Cytokine production from draining LN cells after infection
with L. major. BALB/c mice that were untreated (Control), treated with
PT and control antibody (controlAb), or treated with PT and anti–IL-12
(n 5 5 for each group) were infected in the footpad with L. major. Cells
from draining popliteal LNs were isolated 6 wk after infection and cul-
tured with or without SLA (2.5 mg/ml) for 24 h (for measuring IL-10 and
TNF-a production) or 48 h (for measuring INF-g and IL-4 production).
(A) IFN-g production. (B) IL-4 production. (C) TNF-a production. (D)
IL-10 production. Data are presented as mean value 6 SD for five indi-
vidual mice, and are representative of two separate experiments produc-
ing similar results. *P , 0.005; **P . 0.5.1610 Gi Protein Signaling and Th1 Differentiation
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